Message from the President
Update: June 25, 2026
I would like to express my sincere appreciation for your continued support and trust.
Guided by our Mission— “To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide”—the Sumitomo Pharma Group is devoted to the research and development of innovative and useful therapeutic treatments globally, with a particular focus on Japan and the United States.
I would like to present an overview of our business for fiscal year 2025.
In May 2025, we launched “Reboot 2027 - Reboot for a Strong Sumitomo Pharma,” which outlines our activity policy through fiscal year 2027. In fiscal year 2025, the first year of this plan, we implemented various measures toward rebuilding ourselves as an R&D-driven pharmaceutical company. Under disciplined cost management, we worked to expand sales of our key products and to focus management resources on priority areas, including the reorganization of our Asia business.
As a result, we achieved record-high earnings, with revenue of 453.3 billion yen (an increase of 54.5 billion yen year-on-year), core operating profit of 105.9 billion yen (an increase of 62.8 billion yen year-on-year), and net profit of 106.9 billion yen (an increase of 83.2 billion yen year-on-year). In particular, our North America business, led by ORGOVYX® for advanced prostate cancer and GEMTESA® for overactive bladder, drove the growth of the entire Group. In addition, a decrease in SG&A expenses and R&D expenses due to structural reforms, as well as a gain of 49.0 billion yen on the sale of a portion of our equity interest in the Asia business, contributed to the increase in profit.
In the regenerative medicine/cell therapy business, in March 2026 we obtained conditional and time-limited approval in Japan for the manufacturing and marketing authorization of the allogeneic iPS cell derived dopaminergic neural progenitor cell product AMCHEPRY®, the world’s first iPS cell‑derived regenerative medicine. We will steadily conduct a post‑marketing clinical study and a post-marketing surveillance to obtain full approval, while also advancing Phase 1/2 clinical studies in the United States, aiming for this product to become a game changer in the treatment of Parkinson’s disease and to benefit more patients.
As progress under Reboot 2027 exceeded our initial expectations and we anticipate achieving our financial targets ahead of schedule, we established a new growth strategy in March 2026, “Boost 2028 - Accelerating Strong Sumitomo Pharma.” Under Boost 2028, we will further strengthen our earnings base by maximizing the value of key products, particularly ORGOVYX® and GEMTESA®. In R&D, we will prioritize two programs—enzomenib and nuvisertib, currently under development for acute leukemia and myelofibrosis respectively—as core drivers of our next-generation revenue base, allocating resources accordingly. We will also promote development through partnerships at the appropriate time, with the aim of achieving the earliest possible market launch. Furthermore, while maintaining financial discipline, we will enhance our R&D capabilities focusing on the oncology and psychiatry & neurology (CNS) areas, aiming to continuously create innovative therapies.
To further ensure the execution of this growth strategy, we conducted a public offering in April 2026 to strengthen our financial foundation and secure funds necessary for growth investments. As a result, we have secured funding for growth investments, including R&D investments, capital expenditures, investments and loans to affiliates, and strategic investments, while also improving our financial position through debt repayment.
While we will continue our efforts to improve our financial base to achieve sustained growth and enhance medium- to long-term corporate value, given that a significant portion of our profits currently consists of non-recurring items and that the external environment remains uncertain, the dividend forecast for the fiscal year ending March 31, 2027 has yet to be determined and will be decided based on future business performance trends. Taking into account the progress of Boost 2028, we will consider resuming dividend payments at the earliest possible opportunity.
Going forward, we aim to establish ourselves as a “Global Specialized Player,” where a Value Creation Cycle is firmly in place while maintaining an optimal balance between strengthening our earnings base and making forward-looking investments.
We also value proactive dialogue with our diverse stakeholders, including patients and their families, healthcare professionals, shareholders and investors, employees, business partners, and local communities. By strengthening our corporate governance framework and ensuring compliance across our operations, we will work to continuously enhance corporate value and contribute to the realization of a sustainable society.
We sincerely appreciate your continued understanding and support.
Representative Director,
President and CEO
Sumitomo Pharma Co., Ltd.
June 2026